SHORT INTEFERING RNA (siRNA) AS A NOVEL THERAPEUTIC
Identifieur interne : 000F57 ( Main/Exploration ); précédent : 000F56; suivant : 000F58SHORT INTEFERING RNA (siRNA) AS A NOVEL THERAPEUTIC
Auteurs : Peter N. Pushparaj [Singapour] ; Alirio J. Melendez [Singapour]Source :
- Clinical and Experimental Pharmacology and Physiology [ 0305-1870 ] ; 2006-05.
English descriptors
- Teeft :
- Acad, Acute liver failure, Adult mice, Angiogenesis, Antisense, Antisense oligonucleotides, Antisense strands, Authors journal compilation, Bace1, Biol, Blackwell publishing asia, Caenorhabditis elegans, Cancer gene, Cell culture, Cell death, Clinical trials, Dominant gene disorders, Dsrna, Effective delivery systems, Elegans, Expression vectors, Functional genomics, Fusion protein, Gene, Gene expression, Gene function, Growth factor, Human cells, Human diseases, Human genome, Human virus, Intense research efforts, Interference rnas, Larger dsrnas, Major obstacle, Mammalian cells, Mirna molecules, Mirnas, Mouse model, Mrna, Multiple genes, Multiple sirnas, Mutation, Natl, Natl acad, Neurodegenerative disorders, Neuron, Nucleic, Nucleic acids, Ocular neovascularization, Pathway, Present review, Proc, Rna, Rnai, Rnai technologies, Rnai vectors, Sequence homology, Short interference, Short rnas, Sirna, Sirna delivery, Sirna therapeutics, Sirna therapy, Sirnas, Synthetic sirnas, Tail vein injections, Target mrna, Target tissues, Therapeutic intervention, Therapeutic purposes, Therapeutic strategy, Therapeutics, Various research groups, Vegf, Vegf receptor, Viral, Viral infections, Viral vectors, Vivo, Vivo delivery.
Abstract
1 RNA interference (RNAi) is a robust method of post‐transcriptional silencing of genes using double‐stranded RNA (dsRNA) with sequence homology driven specificity. The dsRNA can be between 21 and 23 nucleotides long: this is converted to small interfering RNA (siRNA), which then mediates gene silencing by degradation/blocking of translation of the target mRNA. 2 RNA interference provides a simple, fast and cost‐effective alternative to existing gene targeting approaches both in vitro and in vivo. The discovery of siRNAs that cause RNAi in mammalian cells opened the door to the therapeutic use of siRNAs. Highly intense research efforts are now aimed at developing siRNAs for therapeutic purposes. 3 Recent advances in the design and delivery of targeting molecules now allow efficient and highly specific gene silencing in mammalian systems. Synthetic siRNA libraries targeting thousands of mammalian genes are publicly available for high‐throughput genetic screens for target discovery and validation. Recent studies have demonstrated the clinical potential of aptly designed siRNAs in various types of viral infections, cancer and renal and neurodegenerative disorders. 4 The present review provides insight into the novel therapeutic strategies of siRNA technology, which is the latest development in nucleic acid‐based tools for knocking down gene expression, and its potential for silencing genes associated with various human diseases.
Url:
DOI: 10.1111/j.1440-1681.2006.04399.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000756
- to stream Istex, to step Curation: 000736
- to stream Istex, to step Checkpoint: 000224
- to stream Main, to step Merge: 000F63
- to stream Main, to step Curation: 000F57
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">SHORT INTEFERING RNA (siRNA) AS A NOVEL THERAPEUTIC</title><author><name sortKey="Pushparaj, Peter N" sort="Pushparaj, Peter N" uniqKey="Pushparaj P" first="Peter N" last="Pushparaj">Peter N. Pushparaj</name></author><author><name sortKey="Melendez, Alirio J" sort="Melendez, Alirio J" uniqKey="Melendez A" first="Alirio J" last="Melendez">Alirio J. Melendez</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:69811272A7DC4A9B533E0A8A551493D3BA417829</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1111/j.1440-1681.2006.04399.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-VH1SL6HW-S/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000756</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000756</idno><idno type="wicri:Area/Istex/Curation">000736</idno><idno type="wicri:Area/Istex/Checkpoint">000224</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000224</idno><idno type="wicri:doubleKey">0305-1870:2006:Pushparaj P:short:intefering:rna</idno><idno type="wicri:Area/Main/Merge">000F63</idno><idno type="wicri:Area/Main/Curation">000F57</idno><idno type="wicri:Area/Main/Exploration">000F57</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">SHORT INTEFERING RNA (siRNA) AS A NOVEL THERAPEUTIC</title><author><name sortKey="Pushparaj, Peter N" sort="Pushparaj, Peter N" uniqKey="Pushparaj P" first="Peter N" last="Pushparaj">Peter N. Pushparaj</name><affiliation wicri:level="4"><country xml:lang="fr">Singapour</country><wicri:regionArea>Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore</wicri:regionArea><orgName type="university">Université nationale de Singapour</orgName></affiliation></author><author><name sortKey="Melendez, Alirio J" sort="Melendez, Alirio J" uniqKey="Melendez A" first="Alirio J" last="Melendez">Alirio J. Melendez</name><affiliation wicri:level="4"><country xml:lang="fr">Singapour</country><wicri:regionArea>Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore</wicri:regionArea><orgName type="university">Université nationale de Singapour</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Clinical and Experimental Pharmacology and Physiology</title><title level="j" type="alt">CLINICAL EXPERIMENTAL PHARMACOLOGY PHYSIOLOGY</title><idno type="ISSN">0305-1870</idno><idno type="eISSN">1440-1681</idno><imprint><biblScope unit="vol">33</biblScope><biblScope unit="issue">5‐6</biblScope><biblScope unit="page" from="504">504</biblScope><biblScope unit="page" to="510">510</biblScope><biblScope unit="page-count">7</biblScope><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2006-05">2006-05</date></imprint><idno type="ISSN">0305-1870</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0305-1870</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad</term><term>Acute liver failure</term><term>Adult mice</term><term>Angiogenesis</term><term>Antisense</term><term>Antisense oligonucleotides</term><term>Antisense strands</term><term>Authors journal compilation</term><term>Bace1</term><term>Biol</term><term>Blackwell publishing asia</term><term>Caenorhabditis elegans</term><term>Cancer gene</term><term>Cell culture</term><term>Cell death</term><term>Clinical trials</term><term>Dominant gene disorders</term><term>Dsrna</term><term>Effective delivery systems</term><term>Elegans</term><term>Expression vectors</term><term>Functional genomics</term><term>Fusion protein</term><term>Gene</term><term>Gene expression</term><term>Gene function</term><term>Growth factor</term><term>Human cells</term><term>Human diseases</term><term>Human genome</term><term>Human virus</term><term>Intense research efforts</term><term>Interference rnas</term><term>Larger dsrnas</term><term>Major obstacle</term><term>Mammalian cells</term><term>Mirna molecules</term><term>Mirnas</term><term>Mouse model</term><term>Mrna</term><term>Multiple genes</term><term>Multiple sirnas</term><term>Mutation</term><term>Natl</term><term>Natl acad</term><term>Neurodegenerative disorders</term><term>Neuron</term><term>Nucleic</term><term>Nucleic acids</term><term>Ocular neovascularization</term><term>Pathway</term><term>Present review</term><term>Proc</term><term>Rna</term><term>Rnai</term><term>Rnai technologies</term><term>Rnai vectors</term><term>Sequence homology</term><term>Short interference</term><term>Short rnas</term><term>Sirna</term><term>Sirna delivery</term><term>Sirna therapeutics</term><term>Sirna therapy</term><term>Sirnas</term><term>Synthetic sirnas</term><term>Tail vein injections</term><term>Target mrna</term><term>Target tissues</term><term>Therapeutic intervention</term><term>Therapeutic purposes</term><term>Therapeutic strategy</term><term>Therapeutics</term><term>Various research groups</term><term>Vegf</term><term>Vegf receptor</term><term>Viral</term><term>Viral infections</term><term>Viral vectors</term><term>Vivo</term><term>Vivo delivery</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">1 RNA interference (RNAi) is a robust method of post‐transcriptional silencing of genes using double‐stranded RNA (dsRNA) with sequence homology driven specificity. The dsRNA can be between 21 and 23 nucleotides long: this is converted to small interfering RNA (siRNA), which then mediates gene silencing by degradation/blocking of translation of the target mRNA. 2 RNA interference provides a simple, fast and cost‐effective alternative to existing gene targeting approaches both in vitro and in vivo. The discovery of siRNAs that cause RNAi in mammalian cells opened the door to the therapeutic use of siRNAs. Highly intense research efforts are now aimed at developing siRNAs for therapeutic purposes. 3 Recent advances in the design and delivery of targeting molecules now allow efficient and highly specific gene silencing in mammalian systems. Synthetic siRNA libraries targeting thousands of mammalian genes are publicly available for high‐throughput genetic screens for target discovery and validation. Recent studies have demonstrated the clinical potential of aptly designed siRNAs in various types of viral infections, cancer and renal and neurodegenerative disorders. 4 The present review provides insight into the novel therapeutic strategies of siRNA technology, which is the latest development in nucleic acid‐based tools for knocking down gene expression, and its potential for silencing genes associated with various human diseases.</div></front></TEI><affiliations><list><country><li>Singapour</li></country><orgName><li>Université nationale de Singapour</li></orgName></list><tree><country name="Singapour"><noRegion><name sortKey="Pushparaj, Peter N" sort="Pushparaj, Peter N" uniqKey="Pushparaj P" first="Peter N" last="Pushparaj">Peter N. Pushparaj</name></noRegion><name sortKey="Melendez, Alirio J" sort="Melendez, Alirio J" uniqKey="Melendez A" first="Alirio J" last="Melendez">Alirio J. Melendez</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F57 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F57 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:69811272A7DC4A9B533E0A8A551493D3BA417829
|texte= SHORT INTEFERING RNA (siRNA) AS A NOVEL THERAPEUTIC
}}
| This area was generated with Dilib version V0.6.33. |  |